DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Major Depressive Disorder (DSM-V) – Unmet Need – Unmet Need – Treatment-Resistant Depression (US/EU)
Major depressive disorder (MDD) is typically treated with psychotherapy, pharmacotherapy, or a combination of the two. The MDD therapy market is highly genericized; for patients experiencing…
Idiopathic Pulmonary Fibrosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Pirfenidone was the first disease-modifying therapy (DMT) approved for IPF,…
Renal Cell Carcinoma – Geographic Focus: China – China In-Depth – Renal Cell Carcinoma
The renal cell carcinoma (RCC) treatment landscape in China has evolved rapidly since the introduction of targeted therapies, including TKIs (Pfizer’s Sutent and Inlyta, Novartis’s Votrient,…
Obesity – Access & Reimbursement – Access & Reimbursement – Obesity / Overweight (US)
Obesity is a significant public health concern. Although inexpensive phentermine is commonly prescribed for weight management, newer therapies like glucagon-like peptide-1 (GLP-1) receptor agonists…
Treatment Algorithms: Claims Data Analysis – Neuropsychiatric Therapies in Alzheimer’s Disease (US) | 2024
In 2023, Lundbeck / Otsuka’s Rexulti became the first FDA-approved drug to treat agitation associated with Alzheimer’s disease (AD). Other novel agents are now emerging as potential treatments…
